DEGRON THERAPEUTICS
Degron Therapeutics is a leading platform company in discovery of molecular glue degraders for cancer treatment.
DEGRON THERAPEUTICS
Industry:
Biotechnology Health Care
Founded:
2021-01-01
Address:
Shanghai, Shanghai, China
Country:
China
Website Url:
http://www.degrontx.com
Status:
Active
Contact:
021-61215873
Email Addresses:
[email protected]
Total Funding:
54 M USD
Current Advisors List
Investors List
NeuX Capital
NeuX Capital investment in Series A - Degron Therapeutics
BioVenture
BioVenture investment in Series A - Degron Therapeutics
Baidu Ventures
Baidu Ventures investment in Series A - Degron Therapeutics
Med-Fine Capital
Med-Fine Capital investment in Series A - Degron Therapeutics
Dyee Capital
Dyee Capital investment in Series A - Degron Therapeutics
Cowin Venture
Cowin Venture investment in Series A - Degron Therapeutics
Official Site Inspections
http://www.degrontx.com Semrush global rank: 6.69 M Semrush visits lastest month: 874
- Host name: 47.103.15.114
- IP address: 47.103.15.114
- Location: Hangzhou China
- Latitude: 30.294
- Longitude: 120.1619
- Timezone: Asia/Shanghai
More informations about "Degron Therapeutics"
Degron Therapeutics - Crunchbase Company Profile
Degron Therapeutics announced a multi-target collaboration and exclusive license agreement with Takeda to discover molecular glue degraders. This partnership includes a $1.2 billion milestone deal.See details»
Degron Therapeutics - LinkedIn
Degron Therapeutics aims to become a global leader in the discovery and development of a new class of targeted protein degradation therapeutics, small molecule molecular glue degrader (MGD) drugs.See details»
Degron Therapeutics Company Profile 2024: Valuation, Funding ...
Degron Therapeutics General Information Description. Developer of molecular glue-based small-molecule drugs. The company mainly develops innovative protein degradation drugs, it uses …See details»
Degron Therapeutics - Overview, News & Similar companies
Degron Therapeutics contact info: Phone number: +86 2161215873 Website: www.degrontx.com What does Degron Therapeutics do? Dago Bio aims to become the world's leading research …See details»
Degron Therapeutics - Craft
Degron Therapeutics $22 m in total funding,. See insights on Degron Therapeutics including office locations, competitors, revenue, financials, executives, subsidiaries and more at Craft.See details»
Degron Therapeutics - VentureRadar
"Degron Therapeutics is a biotechnology company advancing human health by developing novel medicines using its robust molecular glue-based targeted protein degradation drug discovery …See details»
Degron Therapeutics - Company info. interviews, news
Nov 14, 2022 11 AI-powered Drug Discovery Startups Founded in 2021 Nov. 14, 2022 The community of AI-driven biotech companies is continuously expanding, adding new players to …See details»
Degron Therapeutics won the 2023 BRACE Award Venture …
Dec 18, 2023 For more information, please visit www.degrontx.com. Prev：Degron Therapeutics Wins the Second Prize in 2023 Women’s Venture Competition, the First Asian Company to …See details»
Degron Therapeutics Announces Multi-Target Collaboration and …
May 23, 2024 Degron Therapeutics ("Degron"), the company using its molecular glue-based targeted protein degradation drug-discovery platform to advance human health, today …See details»
Media Report_Degron Therapeutics
Degron Therapeutics aims to become a global leader in the discovery and development of a new class of targeted protein degradation therapeutics, small molecule molecular glue degrader …See details»
Degron Therapeutics Raises $22M Series A Financing to ... - BioSpace
SAN DIEGO and SHANGHAI, June 9, 2022 /PRNewswire/ -- Degron Therapeutics (“Degron”), a biotechnology company developing a new class of small-molecule medicines that target …See details»
Degron Therapeutics Announces Multi-Target Collaboration and …
May 23, 2024 Collaboration will leverage Degron's GlueXplorer ® platform to discover novel molecular glue degraders for multiple targets in oncology, neuroscience, and inflammation . …See details»
上海达歌生物医药科技有限公司（简称“达歌生物”）
达歌生物旨在成为全球领先的创新型蛋白降解药物——分子胶水类小分子新药研发公司。由世界一流的管理者和科学领袖组成的具有国际化视野和丰富行业经验的达歌团队，将在全新的，尤其 …See details»
Degron Therapeutics Wins the Second Prize in 2023 Women’s …
Oct 18, 2023 Shanghai, China and San Diego, CA, October 18, 2023, Degron Therapeutics Inc. announced today that Degron Therapeutics and its Co-founder and CEO, Lily Zou, Ph.D., …See details»
Degron Therapeutics Raises $22M Series A Financing to Accelerate …
SAN DIEGO and SHANGHAI, June 9, 2022 /PRNewswire/ -- Degron Therapeutics ("Degron"), a biotechnology company developing a new class of small-molecule medicines that target …See details»
Degron Therapeutics - VentureRadar
Degron Therapeutics is a biotechnology company advancing human health by developing novel medicines using its robust molecular glue-based targeted... ... Find out ...See details»
Life At Degron_Degron Therapeutics
Degron Therapeutics aims to become a global leader in the discovery and development of a new class of targeted protein degradation therapeutics, small molecule molecular glue degrader …See details»
Degron raises $22M to develop molecular glue-based protein …
23/06/2022, 11:22 Degron raises $22M to develop molecular glue-based protein degradation platform | BioWorld https://www.bioworld.com/articles/519877-degron-raises ...See details»
Degron Therapeutics Co-Founder Provides New Strategy for …
Jun 27, 2022 Research published in Cell Chemical Biology showed lenalidomide can enhance cancer-treating ability of PD-1 antibody. SAN DIEGO and SHANGHAI, June 27, 2022 …See details»
Degron Therapeutics Co-Founder Provides New Strategy for …
Jun 27, 2022 Research published in Cell Chemical Biology showed lenalidomide can enhance cancer-treating ability of PD-1 antibody. SAN DIEGO and SHANGHAI, June 27, 2022 …See details»